MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

4.500 -0.140 (-3.02%)
Streaming Delayed Price Updated: 10:06 AM EST, Jan 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,091,760
Open 4.670
Bid (Size) 4.490 (3,300)
Ask (Size) 4.500 (900)
Prev. Close 4.640
Today's Range 4.440 - 4.670
52wk Range 1.891 - 6.515
Shares Outstanding 287,686,199
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
AbCellera to Report Full Year 2025 Financial Results on February 24, 2026
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause
From AbCellera Biologics Inc.
Via Business Wire

Performance

YTD
+31.2%
+31.2%
1 Month
+22.0%
+22.0%
3 Month
-21.2%
-21.2%
6 Month
-10.4%
-10.4%
1 Year
+27.5%
+27.5%

More News

Read More
News headline image
AbCellera and Bruker Reach Global Settlement of Patent Litigation
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 6, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
Via Benzinga
News headline image
AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Appoints Dr. Stephen Quake to its Board of Directors
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Biologics Inc (NASDAQ:ABCL) Reports Mixed Q3 2025 Results with Revenue Beat and Wider Loss ↗
Via Chartmill
News headline image
AI Stocks Extend Selloff, Nasdaq 100 Eyes Worst Week Since April: What's Moving Markets Friday? ↗
Via Benzinga
Topics Artificial Intelligence
News headline image
AbCellera Reports Q3 2025 Business Results
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AI Stocks Slide Again, Bitcoin Dips Near $100,000: What's Moving Markets Thursday? ↗
Via Benzinga
Topics Artificial Intelligence
News headline image
AbCellera to Participate at Upcoming Investor Conferences in November and December 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Stock Market Today: Dow Futures Slip, Nasdaq Rises Amid Mixed Trade—AngioDynamics, Entero Therapeutics, Fermi In Focus ↗
Via Benzinga
Topics Stocks
News headline image
Why Did AbCellera's Stock Jump Over 7% After Hours? ↗
Via Benzinga
News headline image
AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575
From AbCellera Biologics Inc.
Via Business Wire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
Via Benzinga
News headline image
AbCellera to Participate at Upcoming Investor Conferences in September
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Expert Outlook: AbCellera Biologics Through The Eyes Of 4 Analysts ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Via Benzinga
News headline image
AbCellera Biologics (ABCL) Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Curious about the stocks that are showing activity after the closing bell on Thursday? ↗
Via Chartmill
News headline image
AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Galaxy Digital, Blaize Holdings, Verizon And Other Big Stocks Moving Higher On Monday ↗
Via Benzinga

Frequently Asked Questions

Is AbCellera Biologics Inc. - Common Shares publicly traded?
Yes, AbCellera Biologics Inc. - Common Shares is publicly traded.
What exchange does AbCellera Biologics Inc. - Common Shares trade on?
AbCellera Biologics Inc. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for AbCellera Biologics Inc. - Common Shares?
The ticker symbol for AbCellera Biologics Inc. - Common Shares is ABCL on the Nasdaq Stock Market
What is the current price of AbCellera Biologics Inc. - Common Shares?
The current price of AbCellera Biologics Inc. - Common Shares is 4.500
When was AbCellera Biologics Inc. - Common Shares last traded?
The last trade of AbCellera Biologics Inc. - Common Shares was at 01/23/26 10:06 AM ET
What is the market capitalization of AbCellera Biologics Inc. - Common Shares?
The market capitalization of AbCellera Biologics Inc. - Common Shares is 1.29B
How many shares of AbCellera Biologics Inc. - Common Shares are outstanding?
AbCellera Biologics Inc. - Common Shares has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story